British Journal of Anaesthesia, 2004, Vol. 92, No. 2 187-194
© 2004 The Board of Management and Trustees of the British Journal of Anaesthesia
Clinical Investigations |
Effect of remifentanil infusion rate on stress response to the pre-bypass phase of paediatric cardiac surgery
1 University Department of Anaesthesia and 2 Bristol Heart Institute, Bristol Royal Infirmary, Upper Maudlin Street, Bristol BS2 8HW, UK. 3 Department of Anaesthesia, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK
*Corresponding author. E-mail: awolfbch@aol.com
Background. Opioids are used routinely to eliminate the stress response in the pre-bypass phase of paediatric cardiac surgery. Remifentanil is a unique opioid allowing a rapidly titratable effect. No data are available regarding a suitable remifentanil dose regimen for obtunding stress and cardiovascular responses to such surgery.
Methods. We recruited 49 infants and children under 5 yr old who were randomized to receive one of four remifentanil infusion rates (0.25, 1.0, 2.5, or 5.0 µg kg–1 min–1). Blood samples were obtained at induction, pre-surgery, 5 min after opening the chest, and immediately pre-bypass. Whole blood glucose was measured at all time points while cortisol and neuropeptide Y (NPY) were measured in the first and last samples. Heart rate and arterial pressure were also recorded.
Results. There was a significant increase in whole blood glucose 5 min after opening the chest and pre-bypass (P=0.009, P=0.002) in patients receiving remifentanil 0.25 µg kg–1 min–1, but not in those receiving higher doses. Increased remifentanil dosage was associated with reduced plasma cortisol during surgery (P<0.001). Baseline NPY showed considerable variation and there was no association between pre-bypass NPY and remifentanil dose. There was a significantly higher heart rate at the pre-bypass stage of surgery in the remifentanil 0.25 µg kg–1 min–1 group compared with higher doses (P=0.0006). Four out of five neonates with complex cardiac conditions showed severe bradycardia associated with remifentanil.
Conclusions. In infants and children under 5 yr, remifentanil infusions of 1.0 µg kg–1 min–1 and greater can suppress the glucose increase and tachycardia associated with the pre-bypass phase of cardiac surgery, while 0.25 µg kg–1 min–1 does not. Remifentanil should be used with caution in neonates with complex congenital heart disease.
Br J Anaesth 2004; 92: 187–94
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Zaballos, C. Jimeno, J. Almendral, F. Atienza, D. Patino, E. Valdes, J. Navia, and M. J. Anadon Cardiac electrophysiological effects of remifentanil: study in a closed-chest porcine model Br. J. Anaesth., August 1, 2009; 103(2): 191 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Steinlechner, M. Dworschak, B. Birkenberg, T. Lang, A. Schiferer, A. Moritz, B. Mora, and A. Rajek Low-dose remifentanil to suppress haemodynamic responses to noxious stimuli in cardiac surgery: a dose-finding study Br. J. Anaesth., May 1, 2007; 98(5): 598 - 603. [Abstract] [Full Text] [PDF]
|
|